Zebrafish: Speeding Up the Cancer Drug Discovery Process

Patricia Letrado[1,2], Irene de Miguel[2], Iranzu Lamberto[1], Roberto Díez-Martínez[1], and Julen Oyarzabal[2]

Abstract

Zebrafish (*Danio rerio*) is an ideal *in vivo* model to study a wide variety of human cancer types. In this review, we provide a comprehensive overview of zebrafish in the cancer drug discovery process, from (i) approaches to induce malignant tumors, (ii) techniques to monitor cancer progression, and (iii) strategies for compound administration to (iv) a compilation of the 355 existing case studies showing the impact of zebrafish models on cancer drug discovery, which cover a broad scope of scenarios. Finally, based on the current state-of-the-art analysis, this review presents some highlights about future directions using zebrafish in cancer drug discovery and the potential of this model as a prognostic tool in prospective clinical studies. *Cancer Res; 78(21); 6048–58. ©2018 AACR.*

Introduction

Cancer is a worldwide disease, being one of the main causes of morbidity and mortality at present. According to the World Health Organization, there will be an increase of 18.1 million new cancer cases and 9.6 million cancer deaths (1).

Traditionally, the murine model has been used in research as an *in vivo* model organism. However, *Danio rerio*, also known as the zebrafish, owing to its small size, heavy brood, and rapid maturation time, has emerged as an important new cancer model that complements what can traditionally be achieved in mice and cell culture systems. A wide range of assays can be carried out in this model, from target discovery, target validation, or toxicological studies to the generation of tumors to perform the corresponding *in vivo* efficacy tests (e.g., screening molecules; refs. 2, 3).

The zebrafish model possesses unique advantages that establish it as a versatile tool in research. (i) Zebrafish generates large numbers of progeny, offering high confidence in statistical analysis (4). (ii) Human and zebrafish share a high grade of similarity: 71% of human proteins and 82% of disease-causing human proteins have an ortholog in zebrafish (5). (iii) Husbandry expenses are reduced compared with mammals, owing to the inexpensive maintenance that they require (4). (iv) Zebrafish absorbs molecules that are dissolved in water, allowing feasible drug administration (6). (v) Some processes can be directly observed in the living animal due to the transparency of zebrafish embryos and the recent development of the *casper* zebrafish line, which is deficient in pigments (7). (vi) Many zebrafish disease models have been described so far due to the development of transgenic and mutant lines (8).

Zebrafish as a Model Organism in Cancer Research

In terms of cancer research, the zebrafish model has advantages against traditional cell culture assays, as a broader range of phenotypes can be tested (9). Zebrafish and mammals share common molecular pathways of tumor progression (10). Likewise, more than 130 distinct genes in zebrafish liver tumors present similar expression to liver human cancer profiles, correlating with histologic tumor type, grade, and stage. In fact, Zheng and colleagues proved that transgenic zebrafish models share molecular signatures with human hepatocellular carcinoma (11).

There are several approaches to generate human cancer in zebrafish, such as development of mutant and transgenic lines and transplantation of tumor cells (Fig. 1A). Each methodology has several advantages and disadvantages, which are described in Supplementary Table S1. The selection of the zebrafish stage in which experimentation should be carried out depends on the aim of the study, as each developmental stage presents some benefits (Supplementary Table S2). Embryos are most commonly used when the main purpose of the study is the visualization of a concrete tumor process, as their bodies are transparent and allow for microscopy observation. In addition, cancer develops more rapidly in embryos, showing tumor formation by 2 days after the induction. Consequently, they could be employed in projects that demand rapidity, such as imaging cancer processes or screening campaigns. By contrast, adults offer a more realistic *in vivo* model, as all of their organs and immune systems are developed; however, cancer establishment requires from 10–14 days to 1 month (12).

Mutant lines

The mutated cancer driver genes usually dominate cancer proceedings and determine the future of tumorigenesis (13). However, cancer initiation processes cannot be observed, and some operable and time-saving approaches are necessary to manipulate the zebrafish genome and to mimic cancer

[1]Ikan Biotech SL, The Zebrafish Lab Department, Centro Europeo de Empresas e Innovación de Navarra (CEIN), Noain, Spain. [2]Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.

Corresponding Authors: Roberto Díez-Martínez, Ikan Biotech SL, Noain, Navarra 31110, Spain. Phone: 0034848680200; E-mail: roberto.diez@ikanbiotech.com; and Julen Oyarzabal, julenoyarzabal@unav.es

AACR

Figure 1.
A, Methods of cancer generation in adult and embryo zebrafish. **B,** Transplant assays in zebrafish.

initiation and progression. There are different ways to induce cancer in zebrafish, such as chemical mutagenesis, irradiation mutagenesis, insertional mutagenesis, which can be transposon-based, or viral vector mutagenesis. Until now, researchers forced the development of several cancer types using chemicals by adding carcinogens to the water, such as dibenzo(a,l)pyrene (DBP), 7,2-dimethylbenz(a)anthracene (DMBA), N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), N-dimethylnitrosamine (DEN), N-nitrosodiethylamine (NDMA), and N-ethyl-N-nitrosourea (ENU; Supplementary Table S3).

The genome engineering field has experienced an unprecedented rate of growth in recent years since the introduction of designer endonucleases. Genome engineering has not gone far in the field of zebrafish, and researchers use reverse genetics to induce cancer in zebrafish. These methods could imply the inactivation of a concrete gene or the conditional gene regulation through genome editing. The most used techniques to edit the genome and its application in zebrafish is shown in Supplementary Table S4. Other techniques to perform reverse genetic alterations such as morpholinos and RNAi have been less studied due to the limitations that are present (14, 15).

Transgenic lines

Researchers induce transgenic zebrafish models by microinjecting exogenous DNA into one-cell-stage zebrafish embryos, which originate misexpression of wild-type or constitutively active from oncogenes under a zebrafish tissue-specific promoter (16). The major drawback of this method is the difficulty in generating stable lines, as the deleterious effects that strong oncogenes could cause. Thus, researches have established conditional transgenic approaches, which could be spatial or temporal control. Spatial control restricts the expression of oncogenes to a specific tissue based on the use of tissue-specific promoters (17). Some methods that allow spatial control are the Gal4/UAS system, site-specific recombinases such as Cre/loxP, Flp/frt, phiC31, and Dre/rox-system (18–22). Temporal control of oncogene expression or inactivation of tumor suppressors can be achieved by heat shock, hormones, Tet-On and Tet-Off system, and optogenetics. Several examples of cancer models carried out in zebrafish using genetics approaches are shown in Supplementary Table S5.

Transplantation of tumor cells in zebrafish

Another approach to generate cancer in zebrafish is the transplantation of tumor cells. Diverse engraftment assays can be carried out in zebrafish (Fig. 1B). This model of cancer induction is an ideal tool to understand the processes of angiogenesis, tumor cell extravasation, migration, and metastasis (23–25). This procedure has many variables to consider, such as the origin of the donor material. Most of the studies are criticized for use of established cell lines to carry out xenotransplantation assays. This is not considered to be presenting the same conditions of a cancer, as it has been proven that the tumor microenvironment changes spatially and temporally (26). In addition, there is heterogeneity in a tumor, as well as genetic evolution that a commercialized cell line cannot offer (27). Another variable is the microinjection site of the tumor cells, which can vary depending on the developmental stage of the zebrafish. Yolk is the most common injection location, as it provides a large site to house transplanted cells and facilitate manual transplantation in comparison with other smaller regions also injected in zebrafish, such as the duct of Cuvier,

caudal vain, or heart (26). Cells to be injected require *in vivo* pretreatment with cell membrane stains such as CMDiL or transfection to express GFP for visualization after transplant because of the fluorescent signal (26). At present, it is common to screen embryos injected with the appropriate number of cells, as it is still challenging to obtain a reproducible volume of cell administration (28).

One of the main drawbacks of transplantation is the immune rejection of the inoculated tumor cells. In mouse models, a strategy to avoid that process is the use of the NOD/SCID mouse, which presents multiple immunologic alterations, such as the immunosuppression of T, B, and natural killer cells (29). In addition, some chemicals and irradiation are able to act as suppressors of the immune system (30). Zebrafish embryos have not completely developed their innate and adaptive immune system until 21 days of life (31). At that moment, immature T and B cells reach the thymus, finalizing the process of immune maturation (32). This lack of immune defense until 3 to 4 days post fertilization (dpf) prevents the requirement of immunosuppression, and thus, an embryo model is preferable in transplantation assays (33).

In contrast, adults require immune system ablation to avoid engraftment rejection. An important fact to take into account in zebrafish cancer models is the stage in which the assays are carried out. Methods applied to achieve immunosuppression in adult zebrafish are similar to mouse model approaches. Traver and colleagues proved that sublethal radiation (20–25 Gy) produced immune ablation and 90% survival (34). Subsequently, hematopoiesis is reinitiated 12 days after irradiation, and the marrow is fully restored by 20 days after irradiation, killing engrafted cells. In embryos 6 dpf to 1 month old, 15 Gy of gamma-irradiation can ablate T cells (35). Another strategy for immunosuppression is chemical treatment with dexamethasone. This treatment suppresses T and B cells, allowing solid tumor transplantation (36). The 5-day-old zebrafish embryos could be immunosuppressed with 250 mg/mL of dexamethasone 1 to 3 days before transplant (35). Furthermore, transplant could be carried out in immune-compromised zebrafish, allowing long-term engraftment assays and avoiding preconditioning (37). Some immunocompromised transgenic zebrafish have been developed, such as *recombinant activating gene 1* (rag 1) or *v-myb avian myeloblastosis viral oncogene homolog* (myb) mutants. However, these mutants are not commonly used in transplant experiments because the lines are difficult to maintain, and they have other associated diseases (38, 39). Most recently, a *recombination activating gene 2* (rag 2) mutant has been used to transplant tumor cells (40). The major disadvantage of the immunosuppressant method is the inability to study the relationship between immune cells and tumor growth (37).

The transplantation of tumor cells from a donor fish to a genetically identical recipient, known as clonal or syngeneic fish, avoids the immunosuppression requirement (41). In this case, as the immune system is fully activated, the study of interaction between immune cells and tumor is feasible, as is long-term engraftment. However, this method has the limitation of the complexity in the line achievement (37). Zhang and colleagues developed a novel tumor cell transplantation strategy without immunosuppression requirement. This method consists of transplanting irradiated human tumor cells into a zebrafish embryo and retransplanting nonirradiated cells into the same zebrafish 3 months later (42).

Allotransplantation of zebrafish tumor cells. Allogenic transplantation is the transfer of cells, organs, or tissues from one individual into another of the same species. In allograft assays, donor zebrafish suffering from cancer could be obtained by all the methods previously described. Zebrafish recipients require preconditioning treatment if they are not syngeneic or immunosuppressed individuals (Supplementary Table S6).

Xenotransplantation of tumor cells. Xenografting is the process of implanting living tumor cells from one species to another. Lee and colleagues performed the first xenotransplant of human cancer cells to zebrafish embryos to resemble melanoma (43). Tumor cell behavior in zebrafish xenograft models correlates with human cancers (44). Most of the assays carried out are implemented in zebrafish embryos owing to the advantages that this developmental stage offers (Supplementary Table S7).

However, Stoletov and colleagues transplanted several tumor cell lines, such as fibrosarcoma (HT1080) and melanoma (MDA-435, B16), into juvenile 25- to 30-day-old zebrafish treated with dexamethasone to study metastasis by confocal imaging and histology assays (35).

An emerging approach to translational cancer research is the patient-derived xenograft in zebrafish embryos (zPDX). Tumor cells from primary or metastatic human cancers collected by surgery or biopsy procedures are transplanted into zebrafish. This approach provides information about the effectiveness of a treatment, as cells have the same molecular, genetic, and clinical characteristics as the donor. PDX have been broadly developed in mouse models. However, this model presents some limitations that zPDX overcome such as the time required to develop tumor and sample quantity required from each patient (45). Models of several cancer types have been developed using this technique as gastric, breast, or neuroendocrine cancers (46–48). Furthermore, Fior and colleagues showed the reliability of this model by comparing responses to chemotherapy and biological therapies between patients and colorectal zPDX (49, 50).

Orthotopic transplantation of tumor cells. Another approach to xenograft experiments is the orthotopic transplantation of tumor cells. This consists of cell implantation into the same site or organ in which cancer has developed in the donor. Some orthograft assays performed in zebrafish are shown in Supplementary Table S8.

Zebrafish embryos are transparent, allowing visual observation of labeled tumor cells by imaging equipment. Consequently, embryos are the most common stage selected for this sort of study. However, they have not developed every adult organ yet, limiting the tissues where orthotopic transplantation could be performed. In most of the transplantation experiments, cells are inoculated into the yolk of zebrafish embryos, avoiding an orthograft approach. In other cases, it is not possible due to the absence of a concrete organ in zebrafish, such as for breast, lung, or prostate cancer (26). Therefore, Eden and colleagues successfully transplanted mouse tumor cells into the brain of a 30-day-old adult zebrafish previously immunosuppressed with dexamethasone (51). The orthotopic transplantation is more efficient and closer to human metastasis (52). The main disadvantage of this method is the time-consuming and complex nature of the procedure, as well as the limitation of imaging monitoring.

Monitoring Cancer Processes in Zebrafish

Once the cancer induction or engraftment is accomplished, *in vivo* monitoring of tumor processes in zebrafish requires specific and expensive imaging techniques and qualified personnel. Some of the approaches used in cancer monitoring in zebrafish are shown in Supplementary Table S9.

In terms of transplantation assays, there are some strategies to track and label *in vivo* tumor cells using fluorescence microscopy such as fluorescent protein-based reporters or labeling approaches without the gene transfer requirement. At present, membrane dyes as lipophilic carbocyanine dyes (DiO, DiI, DiD, and DiR) have become routinely used to image real-time cancer process at the single-cell level (53).

Furthermore, many imaging methods have been recently developed to enable more accurate imaging analysis. Ghotra and colleagues established a quantitative bioimaging platform to study human cancer dissemination in a xenograft assay (54). Kumar and colleagues described 3D-fluorescence imaging using angularly multiplexed optical projection tomography with compressive sensing to observe tumor progression and vasculature development in live, nonpigmented adult zebrafish (55). In terms of screening assays, in which researchers need to analyze large numbers of images, Pardo-Martin and colleagues developed a vertebrate automated screening technology (VAST) that allows automatic manipulation and imaging collection (56). Then, this tool was improved as the VAST BioImager system, providing automatic handling, positioning, orientating, and high-resolution imaging collection (57).

As has been previously introduced, zebrafish is a very versatile model, which allows the development of many transgenic individuals, improving the study of cancer processes. White and colleagues described a transparent adult zebrafish called *casper*, which has homozygous mutations in two pigmentation loci (7). Benjamin and Hynes were able to visualize *in vivo* metastasis by using this zebrafish mutant after the ZMEL1 cell transplantation (58). Heilmann and colleagues developed a quantitative system to study metastasis to end up with the semiquantitative detection and low signal-to-noise ratio analyses (59). Chen and colleagues created a transgenic line to facilitate luciferase-based imaging in zebrafish, allowing deep tissue visualization in freely swimming animals (60). Furthermore, some transgenic zebrafish lines have the vasculature marked, such as *fli-GFP*, *mtie2-GFP*, and *flik-EGFP* (61–63).

Tumor cell transplantation methods together with the diverse available imaging tools serve to visualize and clarify the insight of tumor processes. (i) Park and colleagues described pancreatic tumor initiation in a KRASG12V transgenic zebrafish model (64). (ii) Neovascularization and behavior of metastatic adenocarcinoma MD-435 cells were visualized in a *fli2-EGFP* transgenic model (35). (iii) Ghotra and colleagues observed migration and dissemination of prostate CMDil-labeled cells transplanted into a *flik-EGFP* transgenic zebrafish (54). (iv) Invasion assays were carried out by xenografting human tumor cells into the same transgenic zebrafish (65). (v) Tumor and immune system interaction was optically studied by Wang and colleagues when human ovarian cells were transplanted into vascularized-labeled zebrafish (66).

Other *ex vivo* approaches monitor tumor processes in ways that differ from imaging. For instance, xenotransplantation observation could be performed by dissociating injected embryos into a

single-cell suspension and counting the average number of fluorescent cells with a microscope (67). In other studies, qPCR was performed to detect a cancer-specific gene or human housekeeping gene in order to evaluate tumor progression (68, 69).

Zebrafish Cancer Model in Drug Discovery

Because of all the previously described advantages that the zebrafish animal model presents, it has recently stood out in the drug discovery process (i) to identify molecules that specifically ameliorate a disease phenotype and (ii) to perform detailed characterization studies around optimized compounds, focusing not only on efficacy (dose-response) but also on toxicity and/or mechanism. Furthermore, personalized treatments are feasible thanks to the development of zPDX, looking at precision cancer medicine.

In terms of cancer, to the best of our knowledge, there are 355 cases reported in the literature where this animal model became a fundamental tool in the drug discovery process, from the discovery of new compounds, or known drugs, with antitumoral activity to detailed therapeutic assessment of optimized molecules (dose-response, toxicity, and/or pathway studies).

Zebrafish in screening campaigns: Advantages and setup considerations

Small-molecule screens are widely used to identify new therapeutics. In this context, cell-based and biochemical drug screenings have played an important role in the identification of new active molecules from large libraries of compounds. Nevertheless, in recent years, whole organism screenings have emerged as a promising alternative to test thousands of molecules. Zebrafish is undoubtedly an interesting approach for this purpose, representing a reliable, low-cost, and rapid option to perform screenings of large libraries and assess their immediate therapeutic relevance. Rennekamp and Peterson reviewed the advantages in zebrafish chemical screening, its limitations, and the impact of zebrafish on chemical biology (70).

Murphey and Zon broadly reviewed the small-molecule screening methods that could be performed (71). These assays carried out in zebrafish consider *in vivo* small-molecule activity and take into account metabolism, toxicity, pharmacokinetics, pharmacodynamics, and cell–cell interactions, providing important information in an early developmental stage that cannot be obtained with traditional biochemical or cell-based screenings (72). Furthermore, this methodology allows the identification of a therapeutic compound without knowing the exact mechanism of the disease (73). In addition, an advantage against the traditional murine model is the requirement of fewer amounts of experimental chemicals, reducing the difficulty and costs associated with the collection procedures (74).

In terms of logistics, screenings with zebrafish can be adapted from 6- to 384-well plates using a variable number of embryos per well, but assays are commonly conducted in 96-well plates. Until now, distribution of these embryos into plates has mainly been performed by hand, but recently, this process has also been automated (75). This fact, together with the possibility of obtaining large numbers of synchronized embryos, opens the possibility to screen larger compound libraries. Regarding the readout of the screening, a wide variety of scoring phenotypes can be adapted to these screenings, depending on the study goal. Especially interesting are morphology changes that can be easily observed in early stages of life thanks to the transparency of zebrafish larvae. According to assay output, phenotypic screening could be morphologic, therapeutic, pathway, or behavioral (76).

Different libraries of compounds can be used in zebrafish screening, from small collections of characterized compounds to larger libraries of thousands of compounds (77). The election of the drug library applied to the screening test depends on the aim of the study. Novel compounds libraries are applied to identify new chemical series and/or mechanisms of action. The corresponding initial hits may initiate a drug discovery project; on the other hand, testing FDA-approved compounds may lead to drug repositioning.

Compound administration and pharmacokinetics

The classical administration of drug is achieved by dissolving the compound directly in the fish water (8). Zebrafish embryos are able to absorb solubilized compounds, allowing feasible administration (16). Zhang and colleagues showed that 3 dpf zebrafish absorbed drugs through the skin and swallowing (78).

However, this method has associated challenges to overcome, such as the variability in the molecule solubility, possible precipitation, and the permeability of the compound. If the drug is not soluble in water, vehicles such as dimethyl sulfoxide can be used, as zebrafish can survive in solutions of 1% (28). Direct administration requires invasive intraperitoneal or retro-orbital injection, which could prevent long-term drug assays (79, 80). To overcome this drawback, Dang and colleagues developed an oral gavage and anesthesia method in adult zebrafish for cancer preclinical studies (81). Furthermore, artificial oil bodies with phospholipids have been developed in order to obtain noninvasive drug administration (82). Kulkarni and colleagues also reported a novel method for oral administration: inserting a micropipette with a small tip into the mouth and pharynx of adult zebrafish, avoiding the variability when chemicals are added to the aquarium water (83).

In addition, zebrafish recently stood out as a tool to develop and test new drug administration strategies such as nanoparticles (84). Therefore, it is difficult to predict how much drug will be absorbed. Depending on the fish developmental stage, entry sites for small molecules are not the same, and as a consequence, the results of the screening can also be different. In addition to using a whole organism, other aspects such as genetic penetrance, *in vivo* chemical modification, or pharmacokinetics (a critical aspect, elaborated below) can alter the results.

Drugs that target human proteins might have different effects in zebrafish, as they present more than one ortholog to human proteins. However, previous pharmacokinetic studies have demonstrated that zebrafish larvae have the ability to perform phase I and phase II metabolism reactions (85). Drug distribution, metabolism, excretion, and allocation into specific organs are replicated in zebrafish, as they possess a full complement of the major drug-metabolizing cytochrome P450 enzymes presented in humans (86). A similarity between zebrafish and higher vertebrates in terms of blood–brain barrier (BBB) permeability has also been demonstrated (87). Together, these data suggest that this animal model could be an excellent model for studying the pharmacokinetic profile of new drugs, but to date, few examples have been published. Kulkarni and colleagues first described a simple method to study the pharmacokinetics of carbamazepine in adult zebrafish, suggesting

that this animal may be an excellent model for studying oral pharmacokinetic and BBB permeability (83).

Later, Kantae and colleagues published the development of an analytical method based on UPLC and mass spectrometric detection to study paracetamol and its metabolites in zebrafish larvae. They used larvae at 3 dpf and concluded that clearance of paracetamol is lower than in higher vertebrates but correlates well to values in immature individuals, probably due to the immaturity of enzymes in zebrafish at 3 dpf (88). Finally, Zhuo and colleagues reported the study of the pharmacokinetic profile and distribution of tramadol and two metabolites in zebrafish by electrospray ionization-quadrupole-time of flight/ mass spectrometry and gas chromatography/mass spectrometry. They compared the results using different doses and administration methods (oral and intramuscular) and validated their method for the analysis of different tissues, such as brain, eyes, muscle, and gills (89).

Case studies

This review compiles the case studies reported so far. To the best of our knowledge, there are 355 in which zebrafish was employed in any step of the cancer drug discovery process. As shown in Fig. 2A, most of these studies used zebrafish as *in vivo* models to evaluate the antitumoral efficacy of lead compounds, detailed efficacy studies together with toxicity and/or mechanistic studies (named "Compound activity testing"). In these terms, zebrafish assays enable structure–activity relationship analyses of newly designed molecules, natural bioactive extracts, and analogs of known antitumoral compounds (90–92). Furthermore, within the cases encompassed in this classification, other studies employed molecules with known effects against cancer to decipher the underlying mechanism of action, to validate new targets or to identify novel pathways (90–94). On the other hand, zebrafish screenings have become recently widespread because they provide a feasible tool to perform high-throughput phenotypic screens (73). In this regard, we have identified several cases in which this animal model was used to perform phenotypic screenings of a large number of molecules to identify new hits for a drug discovery project (named "Compound screening" in Fig. 2A). In these studies, proprietary as well as commercially available libraries, both focused and diverse, have been used (95, 96). Finally, repurposing of approved drugs using zebrafish to discover a potential antitumoral indication has been less frequently described (named "Drug reprofiling" in Fig. 2A). To the best of our knowledge, despite the cost- and time-effective advantages of this approach, only 5 successful cases of repurposing have been reported to date. All details of these 355 studies are described in the Supplementary Information and report for each of the following: (i) the aim of the study (activity test, screening campaign, or drug reprofiling), (ii) subject matter, (iii) cancer type, (iv) assay type (xenograft, angiogenesis, etc.), and (v) corresponding reference.

The first compound identified by zebrafish screening that reached phase I clinical trial was reported in 2013. This molecule, ProHema, was discovered after testing 2,500 compounds. ProHema is derived from Prostaglandin E2 and increases the engraftment of umbilical cord blood stem cells in transplant assays (97, 98). At the present time, two clinical trials using this compound against hematologic malignancies have been completed (identifier: NCT00890500, NCT02354417; ref. 99). Taking into account the potential immediate impact of drug repositioning on patients,

we want to highlight some successful cases. In 2010, Wang and colleagues identified Rosuvastatin, a compound approved to treat hypercholesterolemia, atherosclerosis, and cardiovascular diseases, as an antiangiogenesis drug. In a zebrafish chemical screening, this drug suppressed prostate tumor growth by inhibiting endothelial cell function (100). Furthermore, at present a phase II clinical trial has been conducted to evaluate the antitumoral effect of Rosuvastatin to treat rectal cancer (identifier: NCT02569645; ref. 99). White and colleagues performed an antimelanoma screening in zebrafish. In this case, inhibitors of dihydroorotate dehydrogenase such as leflunomide, used as arthritis treatment, showed inhibition of transcriptional elongation of genes related with melanoma growth; these molecules have been tested in phase I/II clinical trials for the treatment of human melanoma in combination with vemurafenib (identifier: NCT01611675; refs. 99, 101). On the other hand, using two complementary screenings, Gutierrez and colleagues identified several drugs effective against T-cell acute lymphoblastic leukemia. Although the origin of their antiproliferative activity is unknown, and it is thought to involve several mechanisms of action, zebrafish screening showed the antitumoral activity of perphenazine (PPZ), an FDA-approved antipsychotic drug (102). To date, there is no cancer clinical trial employing this drug (99). Testing a commercial library of pharmacologically active compounds in a transgenic zebrafish screening, Evason and colleagues identified two antidepressants that suppressed the hepatocellular carcinoma phenotype (amitriptyline and paroxetine) by suppressing the β-catenin pathway (103). Furthermore, Fernandez del Ama and colleagues discovered the antimelanoma effects of rapamycin, disulfiram, and tanshinone in synergy with MEK and PI3K/mTOR pathway inhibitors (104). Another successful case of cancer reprofiling in a zebrafish model was the antiangiogenic effect showed by closantel, a veterinary anthelmintic drug (105).

As shown in Fig. 2B, most of the reported studies employed zebrafish (i) to assess the antitumoral activity of compounds by using transgenic zebrafish, phenotype assays, or xenograft experiments, as well as (ii) to resemble a specific human cancer type (named "Specific antitumoral activity"). Furthermore, most of the reported studies test antitumoral effects against more than one cancer type. Many cancer models have been described in zebrafish (16). As shown in the figure, the cancer types most commonly studied in zebrafish in the drug discovery process are breast cancer, leukemia, lung cancer, and melanoma, demonstrating the outstanding versatility of this animal model. As angiogenesis is a crucial process involved in tumor progression and spreading, many anticancer therapies focus on targeting these molecular pathways. Furthermore, lymphatic vessel formation is involved in cancer metastasis and progression, becoming a new target for anticancer therapy (106). The transparency of zebrafish embryos and the development of transgenic zebrafish with labeled vasculature enable the visualization of *de novo* blood and lymphatic vessel formation, providing a feasible zebrafish phenotypic observation to identify hits that disrupt these pathways (studies named "Anti-angiogenic activity" and "Anti-lymphatic activity"; ref. 107). Moreover, signaling pathways involved in embryonic development, such as TGFβ, Notch, or Wnt, as well as cellular mechanisms such as apoptosis and cell-cycle regulation, are also related to cancer development when deregulated (108, 109). In zebrafish, alterations of these pathways can be easily observed

Figure 2.
A, Classification of the 355 reported case studies in zebrafish, cancer drug discovery projects, according to the aim of the study. **B,** Left graph represents studies reported in literature classified by the subject matter. Right graph shows cancer types studied in cases encompass in "Specific anti-tumoral activity." All details about the 355 case studies are described in Supplementary Table S10.

phenotypically as developmental disruptions. Other case studies identified compounds using mutant or transgenic zebrafish to identify antitumoral activity, but not against a specific tumor type (named "Anti-tumoral activity").

Conclusion and Perspectives

The zebrafish *in vivo* model provides many advantages in cancer research in comparison with the broadly used traditional *in vitro* cell model and the *in vivo* murine model. Due to its maintenance costs, work feasibility, and simplicity to obtain cancer pheno-types, zebrafish has recently become a meaningful tool in science. In terms of cancer research, zebrafish allows scientists to study procedures such as tumor formation, migration, and metastasis as well as to perform an agile identification of the optimal molecule, or/and known drug (repositioning), to treat each different tumor types. Some of these strengths are as follows: (i) Adult zebrafish spawns large numbers of embryos in each clutch, providing a high-confidence statistical analysis method (4). (ii) Currently, several approaches to induce cancer in zebrafish have been

broadly described, from mutation and transgenesis to transplantation techniques. (iii) Tumor formation is a rapid process, only requiring from 10–14 days to 1 month, compared with that of the traditional murine model that needs up to 4 months to observe the complete process (12, 110). (iv) Zebrafish cancer has been proven to be similar to human cancer (10). (v) In terms of logistics, embryos can be placed in 96-well plates, allowing high-throughput studies to test thousands of chemical compounds, thereby reducing time and costs in chemical screenings and leading to results of immediate therapeutic relevance (111). (vi) Transparency of the embryos and the development of new mutants without pigmentation, such as the *casper* zebrafish, offer the possibility to visualize all of these cancer processes (7). (vii) Most of the compounds can be dissolved in water as a feasible method of administration (8). (viii) Although there are few cases reported in the literature in which zebrafish was successfully employed in drug discovery and reprofiling, several compounds reached a phase II clinical trial, showing the advantages that the zebrafish animal model provides (99, 100). (ix) Several studies show the reliability of zPDX model for different cancer types as it is able to overcome some drawbacks of the murine PDX such as time required to develop a model ready for preclinical study (45–50).

However, from cancer drug discovery perspective, zebrafish still presents some limitations that should be overcome in a near future. As reported below, there are specific challenges that have to be faced more efficiently; in fact, they require further development and refinement:

- High-resolution imaging techniques. Monitoring cancer in zebrafish needs specific equipment and transgenic animals. In addition, cells should be labeled (7, 112), although new imaging systems have been developed such as a linear-CCD "charge-coupled device"–based flow imaging system that allows high-throughput imaging of dozens of embryos per second (113). Furthermore, real-time zebrafish monitoring has been achieved thanks to the improvement of immobilization techniques. Most of them are based on microfluidic plates and chips that enable cost-effective phenotype-based screenings and feasible drug administration (114, 115).
- Immune system. The majority of studies must be carried out in an embryo stage, as the immune system is not completely developed, and the assays performed in an advanced stage should be immunosuppressed (34, 35). By the application of the techniques described in an advanced development stage, the results would resemble the real behavior of cancer in humans (25). Casey and colleagues achieved the allotransplantation of pediatric brain tumors into immune-competent zebrafish (116). Furthermore, this *in vivo* model has broadened its application in drug discovery processes as it has been recently employed in immunotherapeutic drug screenings (117).
- Compound administration. Direct and long-term administration is a drawback in zebrafish assays, as methods used at

present are very invasive, and it is difficult to predict whether the drug was absorbed by the zebrafish (26). Monstad-Rios and colleagues developed a 3D printed system for cost-effective drug administration in adult zebrafish enabling small-molecular screenings in postembryonic models (118).
- Pharmacokinetics and pharmacodynamics. Although it has been demonstrated that larvae have the ability to perform metabolism reactions, and their drug distribution, metabolism, excretion, and allocation are similar to humans, these fields are scarcely explored in zebrafish (86). A very recent study, using a zebrafish orthotopic glioblastoma xenograft model, was able to monitor compounds crossing the BBB and identify a drug that efficiently passes through the BBB (119).
- Tumor microenvironment. Some cancer processes proven to be very relevant in tumor formation, such as the tumor microenvironment, are seldom studied in zebrafish (120). However, a cancer stem cell xenograft model developed by Chen and colleagues enabled the study of interaction with microenvironment during bone metastasis progression (121).

On the other hand, zebrafish has become a versatile and reliable tool in cancer research due to emerging approaches that may have a huge impact on cancer drug discovery process in the near future:

- Bioenergetic-based screening. Ibjazehiebo and colleagues performed an *in vivo* bioenergetic screening in zebrafish for epilepsy (122). As cancer energy metabolism plays a key role in cell progression, tumor bioenergetics stands out as a new target for cancer therapies (123). Therefore, this approach could be currently applied in antitumoral screenings using zebrafish.
- zPDX. This approach is probably the most relevant, from a translational perspective, in cancer drug discovery using zebrafish. Every patient and its corresponding tumor type may respond in a different manner to drugs; then, efficient models providing fast and reliable assessments for personalized treatments might provide an outstanding added value for precision cancer medicine (49, 124).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL. Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin 2018 Sep 12. doi: 10.3322/caac.21492.
2. Santoriello C, Zon LI. Hooked! Modeling human disease in zebrafish. J Clin Invest 2012;122:2337–43.
3. Langheinrich U. Zebrafish: a new model on the pharmaceutical catwalk. BioEssays 2003;25:904–12.

Letrado et al.

4. Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 2005;4:35–44.
5. Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature 2013;496:498–503.
6. Goessling W, North TE, Zon LI. New waves of discovery: modeling cancer in zebrafish. J Clin Oncol 2007;25:2473–9.
7. White RM, Sessa A, Burke C, Bowman T, Leblanc J, Ceol C, et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell 2008;2:183–9.
8. Lieschke GJ, Currie PD. Animal models of human disease: zebrafish swim into view. Nat Rev Genet 2007;8:353–67.
9. MacRae CA, Peterson RT. Zebrafish as tools for drug discovery. Nat Rev Drug Discov 2015;14:721–31.
10. Lam SH, Wu YL, Vega VB, Miller LD, Spitsbergen J, Tong Y, et al. Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol 2006;24:73–5.
11. Zheng W, Li Z, Nguyen AT, Li C, Emelyanov A, Gong Z. Xmrk, Kras and Myc transgenic zebrafish liver cancer models share molecular signatures with subsets of human hepatocellular carcinoma. PLoS One 2014;9: e91179.
12. Taylor AM, Zon LI. Zebrafish tumor assays: the state of transplantation. Zebrafish 2009;6:339–46.
13. Garraway LA, Lander ES. Lessons from the cancer genome. Cell 2013; 153:17–37.
14. Bill BR, Petzold AM, Clark KJ, Schimmenti LA, Ekker SC. A primer for morpholino use in zebrafish. Zebrafish 2009;6:69–77.
15. Nasevicius A, Ekker SC. Effective targeted gene `knockdown' in zebrafish. Nat Genet 2000;26:216–20.
16. Huiting LN, Laroche F, Feng H. The zebrafish as a tool to cancer drug discovery. Austin J Pharmacol Ther 2015;3:1069.
17. Mayrhofer M, Mione M. The toolbox for conditional zebrafish cancer models. Adv Exp Med Biol 2016;916:21–59.
18. Halpern ME, Rhee J, Goll MG, Akitake CM, Parsons M, Leach SD. Gal4/UAS transgenic tools and their application to zebrafish. Zebrafish 2008;5:97–110.
19. Langenau DM, Feng H, Berghmans S, Kanki JP, Kutok JL, Look AT. Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia. Proc Natl Acad Sci 2005;102:6068–73.
20. Wong RSY. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 2011;30:87.
21. Mosimann C, Puller A-C, Lawson KL, Tschopp P, Amsterdam A, Zon LI. Site-directed zebrafish transgenesis into single landing sites with the phiC31 integrase system. Dev Dyn 2013;242:949–63.
22. Park JT, Leach SD. TAILOR: transgene activation and inactivation using lox and rox in zebrafish. PLoS One 2013;8:e85218.
23. Nicoli S, Ribatti D, Cotelli F, Presta M. Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer Res 2007;67: 2927–31.
24. Stoletov K, Kato H, Zardouzian E, Kelber J, Yang J, Shattil S, et al. Visualizing extravasation dynamics of metastatic tumor cells. J Cell Sci 2010;123:2332–41.
25. Marques IJ, Weiss FU, Vlecken DH, Nitsche C, Bakkers J, Lagendijk AK, et al. Metastatic behaviour of primary human tumours in a zebrafish xenotransplantation model. BMC Cancer 2009;9:128.
26. Wertman J, Veinotte CJ, Dellaire G, Berman JN. The zebrafish xenograft platform: evolution of a novel cancer model and preclinical screening tool. Adv Exp Med Biol 2016;916:289–314.
27. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481: 306–13.
28. Brown HK, Schiavone K, Tazzyman S, Heymann D, Chico TJ. Zebrafish xenograft models of cancer and metastasis for drug discovery. Expert Opin Drug Discov 2017;12:379–89.
29. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/gamma cnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002;100:3175–82.
30. Steel GG, Courtenay VD, Rostom AY. Improved immune-suppression techniques for the exongrafting of human tumours. Br J Cancer 1978; 37:224–30.
31. Lieschke GJ, Trede NS. Fish immunology. Curr Biol 2009;19:R678–82.
32. Lam SH, Chua HL, Gong Z, Lam TJ, Sin YM. Development and maturation of the immune system in zebrafish, Danio rerio: a gene expression profiling, in situ hybridization and immunological study. Dev Comp Immunol 2004;28:9–28.
33. Traver D, Herbomel P, Patton EE, Murphey RD, Yoder JA, Litman GW, et al. The zebrafish as a model organism to study development of the immune system. Adv Immunol 2003;81:253–330.
34. Traver D, Winzeler A, Stern HM, Mayhall EA, Langenau DM, Kutok JL, et al. Effects of lethal irradiation in zebrafish and rescue by hematopoietic cell transplantation. Blood 2004;104:1298–305.
35. Stoletov K, Montel V, Lester RD, Gonias SL, Klemke R. High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish. Proc Natl Acad Sci 2007;104:17406–11.
36. Langenau DM, Ferrando AA, Traver D, Kutok JL, Hezel J-PPD, Kanki JP, et al. In vivo tracking of T cell development, ablation, and engraftment in transgenic zebrafish. Proc Natl Acad Sci 2004;101:7369–74.
37. Moore JC, Langenau DM. Allograft cancer cell transplantation in zebrafish. Adv Exp Med Biol 2016;916:265–87.
38. Wienholds E, Schulte-Merker S, Walderich B, Plasterk RHA. Target-selected inactivation of the zebrafish rag1 Gene. Science 2002;297:99–102.
39. Soza-ried C, Hess I, Netuschil N, Schorpp M, Boehm T. Essential role of c-myb in de fi nitive hematopoiesis is evolutionarily conserved. Proc Natl Acad Sci 2010;107:17304–8.
40. Tang Q, Abdelfattah NS, Blackburn JS, Moore JC. Optimized cell transplantation using adult rag2 mutant zebrafish. Nat Methods 2014; 11:821–4.
41. Smith ACH, Raimondi AR, Salthouse CD, Ignatius MS, Blackburn JS, Mizgirev I V, et al. High-throughput cell transplantation establishes that tumor-initiating cells are abundant in zebrafish T-cell acute lymphoblastic leukemia. Blood 2010;115:3296–303.
42. Zhang B, Shimada Y, Hirota T, Ariyoshi M, Kuroyanagi J, Nishimura Y, et al. Novel immunologic tolerance of human cancer cell xenotransplants in zebrafish. Transl Res 2016;170:89–98.
43. Lee LMJ, Seftor EA, Bonde G, Cornell RA, Hendrix MJC. The fate of human malignant melanoma cells transplanted into zebrafish embryos: Assessment of migration and cell division in the absence of tumor formation. Dev Dyn 2005;233:1560–70.
44. van der Ent W, Burrello C, Teunisse AFAS, Ksander BR, van der Velden PA, Jager MJ, et al. Modeling of human uveal melanoma in zebrafish xenograft embryos. Investig Opthalmology Vis Sci 2014;55:6612–22.
45. Astone M, Dankert EN, Alam K, Hoeppner LH. Fishing for cures: The alLURE of using zebrafish to develop precision oncology therapies. NPJ Precis Oncol 2017;1:39.
46. Wu J-Q, Zhai J, Li C-Y, Tan A-M, Wei P, Shen L-Z, et al. Patient-derived xenograft in zerbafish embryos: a new platform for translational research in gastric cancer. J Exp Clin Cancer Res 2017;36:160.
47. Mercatali L, La Manna F, Groenewoud A, Casadei R, Recine F, Miserocchi G, et al. Development of a patient-derived xenofraft (PDX) of breast cancer bone metástasis in a zebrafish model. Int J Mol Sci 2016;17:E1375.
48. Gaudenzi G, Albertelli M, Dicitore A, Würth R, Gatto F, Barbieri F, et al. Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors. Endocrine 2017;57: 214–9.
49. Fior R, Póvoa V, Mendes RV, Carvalho T, Gomes A, Figueiredo N, et al. Singel-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafis xenofafts. PNAS 2017;114:E8234–E8243.
50. Fazio M, Zon LI. Fishing for answers in precision cancer medicine. Proc Natl Acad Sci USA 2017;114:10206–308.
51. Eden CJ, Ju B, Murugesan M, Phoenix T. Orthotopic models of pediatric brain tumors in zebrafish. Oncogene 2015;34:1736–42.
52. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998;17:279–84.
53. Progatzky F, Dallman MJ, Lo Celso C. From seeing to believing: labelling strategies for in vivo cell-tracking experiments 2013;3:20130001.
54. Ghotra VPS, He S, de Bont H, et al. Automated whole animal bio-imaging assay for human cancer dissemination. PLoS One 2012;7:e31281.
55. Kumar S, Lockwood N, Ramel M-C, Correia T, Ellis M, Alexandrov Y, et al. Quantitative in vivo optical tomography of cancer progression & vasculature development in adult zebrafish. Oncotarget 2016;7:43939–48.

56. Pardo-Martin C, Chang T, Koo BK, Gilleland CL, Wasserman SC, Yanik MF. High-throughput in vivo vertebrate screening. Nat Methods 2010; 7:634–6.

57. Pulak R. Tools for automating the imaging of zebrafish larvae. Methods 2016;96:118–26.

58. Benjamin DC, Hynes RO. Intravital imaging of metastasis in adult zebrafish. BMC Cancer 2017;17:660.

59. Heilmann S, Ratnakumar K, Langdon E, Kansler E, Kim I, Campbell NR. A quantitative system for studying metastasis using transparent zebrafish. Cancer Res 2015;75:4272–82.

60. Chen C-H, Durand E, Wang J, Zon LI, Poss KD. Zebraflash transgenic lines for in vivo bioluminescence imaging of stem cells and regeneration in adult zebrafish. Development 2013;140:4988–97.

61. Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 2002;248:307–18.

62. Motoike T, Loughna S, Perens E, Roman BL, Liao W, Chau TC, et al. Universal GFP reporter for the study of vascular development. Genesis 2000;28:75–81.

63. Cross LM, Cook MA, Lin S, Chen J-N, Rubinstein AL. Rapid analysis of angiogenesis drugs in a live fluorescent zebrafish assay. Arterioscler Thromb Vasc Biol 2003;23:911–2.

64. Park SW, Davison JM, Rhee J, Hruban RH, Maitra A, Leach SD. Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas. Gastroenterology 2008; 134:2080–90.

65. Rouhi P, Jensen LD, Cao Z, Hosaka K, Länne T, Wahlberg E, et al. Hypoxia-induced metastasis model in embryonic zebrafish. Nat Protoc 2010; 5:1911–8.

66. Wang J, Cao Z, Zhang X-M, Nakamura M, Sun M, Hartman J, et al. Novel mechanism of macrophage-mediated metastasis revealed in a zebrafish model of tumor development. Cancer Res 2015;75:306–15.

67. Corkery DP, Dellaire G, Berman JN. Leukaemia xenotransplantation in zebrafish - chemotherapy response assay in vivo. Br J Haematol 2011; 153:786–9.

68. Bentley VL, Veinotte CJ, Corkery DP, Pinder JB, LeBlanc MA, Bedard K, et al. Focused chemical genomics using zebrafish xenotransplantation as a pre-clinical therapeutic platform for T-cell acute lymphoblastic leukemia. Haematologica 2015;100:70–6.

69. Xu W, Foster BA, Richards M, Bondioli KR, Shah G, Green CC. Characterization of prostate cancer cell progression in zebrafish xenograft model. Int J Oncol 2018;52:252–60.

70. Rennekamp AJ, Peterson RT. 15 years of zebrafish chemical screening Andrew. Curr Opin Chem Biol 2015;0:58–70.

71. Murphey RD, Zon LI. Small molecule screening in the zebrafish. Methods 2006;39:255–61.

72. Rihel J, Prober DA, Arvanites A, Lam K, Jang S, Haggarty SJ, et al. Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science 2010;327:348–51.

73. Tamplin OJ, White RM, Jing L, Kaufman CK, Lacadie SA, Li P, et al. Small molecule screening in zebrafish: swimming in potential drug therapies. Wiley Interdiscip Rev Dev Biol 2012;1:459–68.

74. Veinotte CJ, Dellaire G, Berman JN. Hooking the big one: the potential of zebrafish xenotransplantation to reform cancer drug screening in the genomic era. Dis Model Mech 2014;7:745–54.

75. Truong L, Reif DM, Mary LS, Geier MC, Truong HD, Tanguay RL. Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci 2014;137:212–33.

76. Williams CH, Hong CC. Zebrafish small molecule screens: taking the phenotypic plunge. Comput Struct Biotechnol J 2016;14:350–6.

77. Peal DS, Peterson RT, Milan D. Small molecule screening in zebrafish. J Cardiovasc Transl Res 2010;3:454–60.

78. Zhang F, Qin W, Zhang J-P, Hu C-Q. Antibiotic toxicity and absorption in zebrafish using liquid chromatography-tandem mass spectrometry. PLoS One 2015;10:e0124805.

79. Pugach EK, Li P, White R, Zon L. Retro-orbital injection in adult zebrafish. J Vis Exp 2009;34:4–6.

80. Kinkel MD, Eames SC, Philipson LH, Prince VE. Intraperitoneal injection into adult zebrafish. J Vis Exp 2010;30:3–6.

81. Dang M, Fogley R, Zon LI. Identifying novel cancer therapies using chemical genetics and zebrafish. Adv Exp Med Biol 2016;916: 103–24.

82. Chiang C-J, Lin L-J, Yang TY, Chao Y-P. Artificial oil body as a potential oral administration system in zebrafish. J Taiwan Inst Chem Eng 2016;61:46–53.

83. Kulkarni P, Chaudhari GH, Sripuram V, Banote RK, Kirla KT, Sultana R, et al. Oral dosing in adult zebrafish: Proof-of-concept using pharmacokinetics and pharmacological evaluation of carbamazepine. Pharmacol Rep 2014;66:179–83.

84. Evensen L, Johansen PL, Koster G, Zhu K, Herfindal L, Speth M, et al. Zebrafish as a model system for characterization of nanoparticles against cancer. Nanoscale 2016;8:862–77.

85. Alderton W, Berghmans S, Butler P, Chassaing H, Fleming A, Golder Z, et al. Accumulation and metabolism of drugs and CYP probe substrates in zebrafish larvae. Xenobiotica 2010;40:547–57.

86. Goldstone J V., McArthur AG, Kubota A, Zanette J, Parente T, Jönsson ME, et al. Identification and developmental expression of the full complement of cytochrome P450 genes in zebrafish. BMC Genomics 2010;11:643.

87. Jeong J-Y, Kwon H-B, Ahn J-C, Kang D, Kwon S-H, Park JA, et al. Functional and developmental analysis of the blood–brain barrier in zebrafish. Brain Res Bull 2008;75:619–28.

88. Kantae V, Krekels EHJ, Ordas A, González O, van Wijk RC, Harms AC, et al. Pharmacokinetic modeling of paracetamol uptake and clearance in zebrafish larvae: expanding the allometric scale in vertebrates with five orders of magnitude. Zebrafish 2016;13:504–10.

89. Zhuo H, Jin H, Peng H, Huang H. Distribution, pharmacokinetics and primary metabolism model of tramadol in zebrafish. Mol Med Rep 2016;14:5644–52.

90. Zhang J, Liu C, Shi W, Yang L, Zhang Q, Cui J, et al. The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer. Oncotarget 2016;7:41067–80.

91. Tian L, Xie K, Sheng D, Wan X, Zhu G. Antiangiogenic effects of oridonin. BMC Complement Altern Med 2017;17:192.

92. Amawi H, Hussein NA, Karthikeyan C, Manivannan E, Wisner A, Williams FE, et al. HM015k, a novel silybin derivative, multi-targets metastatic ovarian cancer cells and is safe in zebrafish toxicity studies. Front Pharmacol 2017;8:498.

93. Da-Song Y, Qiu-Xia H, Yong-Ping Y, Ke-Chun L, Xiao-Li L. Chemical constituents of Euphorbia tibetica and their biological activities. Chin J Nat Med 2014;12:38–42.

94. Li L, Chen X, Liu CC, Lee LS, Man C, Cheng SH. Phytoestrogen bakuchiol exhibits in vitro and in vivo anti-breast cancer effects by inducing S phase arrest and apoptosis. Front Pharmacol 2016;7:128.

95. Liang F, Han Y, Gao H, Xin S, Chen S, Wang N, et al. Kaempferol identified by zebrafish assay and fine fractionations strategy from dysosma versipellis inhibits angiogenesis through VEGF and FGF pathways. Sci Rep 2015;5:14468.

96. Tran TC, Sneed B, Haider J, Blavo D, White A, Aiyejorun T, et al. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res 2007;67:11386–92.

97. North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007;447:1007–11.

98. Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL, et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 2009;136:1136–47.

99. U.S. National Library of Medicine. Clinical trials database. National Institutes of Health, 2012. Available from:https://clinicaltrials.gov/

100. Wang C, Tao W, Wang Y, Bikow J, Lu B, Keating A, et al. Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur Urol 2010;58: 418–26.

101. White RM, Cech J, Ratanasirintrawoot S, Lin CY, Rahl PB, Burke CJ, et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 2011;471: 518–22.

102. Gutierrez A, Pan L, Groen RWJ, et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Investig 2014;124:644–55.

103. Evason KJ, Francisco MT, Juric V, Balakrishnan S, Lopez Pazmino M del P, Gordan JD, et al. Identification of chemical inhibitors of β-catenin-driven liver tumorigenesis in zebrafish. PLOS Genet 2015; 11:e1005305.

104. Fernandez del Ama L, Jones M, Walker P, Chapman A, Braun JA, Mohr J, et al. Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics. Oncotarget 2016;7: 40348–61

105. Zhu X-Y, Xia B, Liu H-C, Xu Y-Q, Huang C-J, Gao J-M, et al. Closantel suppresses angiogenesis and cancer growth in zebrafish models. Assay Drug Dev Technol 2016;14:282–90.

106. Alitalo A, Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 2012;31:4499–508.

107. Santoro MM. Antiangiogenic cancer drug using the zebrafish model. Arterioscler Thromb Vasc Biol 2014;34:1846–53.

108. Morris S-AL, Huang S. Crosstalk of the Wnt/β-catenin pathway with other pathways in cancer cells. Genes Dis 2016;3:41–7.

109. Tumova L, Pombinho AR, Vojtechova M, Stancikova J, Gradl D, Krausova M, et al. Monensin inhibits canonical wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol Cancer Ther 2014;13: 812–22.

110. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2007;2:247–50.

111. Amatruda JF, Shepard JL, Stern HM, Zon LI. Zebrafish as a cancer model system. Cancer Cell 2002;1:229–31.

112. Zhang L, Alt C, Li P, White RM, Zon LI, Wei X, et al. An optical platform for cell tracking in adult zebrafish. Cytom Part A 2012; 81:176–82.

113. Liu L, Yang G, Liu S, Wang L, Yang L, Qu H, et al. High-throughput imaging of zebrafish embryos using a linear-CCD-based flow imaging system. Biomed Opt Express 2017;8:5651–62.

114. Nady A, Peimani AR, Zoidl G, Rezai P. A microfluidic device for partial immobilization, chemical exposure and behavioural screening of zebrafish larvae. Lab Chip 2017;17:4048–58.

115. Li Y, Yang F, Chen Z, Shi L, Zhang B, Pan J, et al. Zebrafish on a chip: a novel platform for real-time monitoring of drug-induced developmental toxicity. PLoS One 2014;9:e94792.

116. Casey MJ, Modzelewska K, Anderson D, Goodman J, Boer EF, Jimenez L, et al. Transplantation of zebrafish pediatric brain tumors into immunocompetent hosts for long-term study of tumor cell behavior and drug response. J Vis Exp 2017;55712.

117. Hamilton L, Sieger D, Rubio Ruiz B, Unciti-broceta A. A novel zebrafish xenograft model for immunotherapeutic drug screening. Neuro-Oncology 2018;20:i14.

118. Monstad-Rios AT, Watson CJ, Kwon RY. ScreenCube: a 3D printed system for rapid and cost-effective chemical screening in adult zerbafish. Zebrafish 2017;0:1–8.

119. Zeng A, Ye T, Cao D, Huang X, Yang Y, Chen X, et al. Identify a blood-brain barrier penetrating drug-TNB using zebrafish orthotopic glioblastoma xenograft model. Sci Rep 2017;7:14372.

120. Kim IS, Heilmann S, Kansler ER, Zhang Y, Zimmer M, Ratnakumar K, et al. Microenvironment-derived factors driving metastatic plasticity in melanoma. Nat Commun 2017;8:14343.

121. Chen L, Groenewoud A, Tulotta C, Zoni E, Kruihof-de Julio M, van der Horst G, et al. A zebrafish xenograft model for studying human cancer stem cells in distant metástasis and therapy response. Methods Cell Biol 2017;138:471–96.

122. Ibhazehiebo K, Gavrilovici C, de la Hoz C, Ma S, Rehak R, Kaushik G, et al. A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target. Brain 2018;141:744–61.

123. Kee HJ, Cheong J-H. Tumor bioenergetics: an emerging avenue for cancer metabolism targeted therapy. BMB Rep 2014;47:158–66.

124. Baxendale S, van Eeden F, Wilkinson R. The power of zebrafish in personalised medicine. Adv Exp Med Biol 2017;1007:179–97.